Anixa Biosciences Inc (ANIX) – What Are Investment Firms Saying About This Stock?

Anixa Biosciences Inc (NASDAQ:ANIX) has been assigned an average rating of “Hold” from the five ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $8.00.

A number of equities analysts recently commented on the company. Weiss Ratings raised Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a report on Tuesday, October 6th. Finally, Zacks Research downgraded shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th.

Anixa Biosciences Trading Down 0.7%

NASDAQ ANIX opened at $2.65 on Thursday. The business’s 50-day moving average price is $3.07 and its two-hundred day moving average price is $2.98. Anixa Biosciences has a 12 month low of $2.32 and a 12 month high of $5.46. The firm has a market capitalization of $92.11 million, a PE ratio of -8.28 and a beta of 0.47.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). As a group, analysts forecast that Anixa Biosciences will post -0.31 earnings per share for the current fiscal year.

Insider Activity at Anixa Biosciences

In other news, Director Lewis Titterton, Jr. acquired 49,036 shares of the firm’s stock in a transaction dated Wednesday, September 23rd. The stock was bought at an average cost of $2.69 per share, for a total transaction of $131,906.84. Following the completion of the transaction, the director directly owned 1,046,003 shares in the company, valued at $2,813,748.07. This represents a 4.92% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders have acquired 105,724 shares of company stock valued at $303,920. Corporate insiders own 26.40% of the company’s stock.

Hedge Funds Weigh In On Anixa Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Anixa Biosciences during the second quarter valued at $559,000. GSA Capital Partners LLP acquired a new stake in Anixa Biosciences during the 2nd quarter worth about $329,000. CoreCap Advisors LLC grew its holdings in Anixa Biosciences by 19.2% during the 3rd quarter. CoreCap Advisors LLC now owns 62,020 shares of the company’s stock worth $182,000 after acquiring an additional 10,000 shares during the period. Renaissance Technologies LLC raised its position in shares of Anixa Biosciences by 13.6% in the 1st quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock worth $158,000 after acquiring an additional 7,300 shares in the last quarter. Finally, Kestra Advisory Services LLC raised its position in shares of Anixa Biosciences by 96.2% in the 1st quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company’s stock worth $132,000 after acquiring an additional 25,000 shares in the last quarter. Institutional investors and hedge funds own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. Rather than marketing a broad portfolio of commercial products, the company concentrates on advancing novel therapies through research collaborations and clinical development.

Anixa’s cancer programs include a breast cancer vaccine intended to target alpha-lactalbumin, a protein associated with certain breast cancers. The program is being developed in collaboration with researchers at Cleveland Clinic.